Refractory Multiple Myeloma Pipeline Booms as 80+ Companies likely to Enter in the Treatment Domain | Major Companies – Amgen, AbbVie, Takeda Oncology, and Others
DelveInsight’s ‘Refractory Multiple Myeloma Pipeline Insight 2023’ report provides comprehensive global coverage of available, marketed, and pipeline refractory multiple myeloma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the refractory multiple myeloma pipeline domain.
In the ‘Refractory Multiple Myeloma Pipeline Report, a detailed description of the drug is given which includes mechanism of action of the drug, ‘Refractory Multiple Myeloma clinical trial studies, ‘Refractory Multiple Myeloma NDA approvals (if any), and product development activities comprising the technology, Refractory Multiple Myeloma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key Takeaways from the Refractory Multiple Myeloma Pipeline Report
- DelveInsight’s refractory multiple myeloma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for refractory multiple myeloma treatment.
- The leading refractory multiple myeloma companies include NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, Janssen Research & Development, Bristol Myers Squibb, Lava Therapeutics, Prelude Therapeutics, Amgen, Pfizer, Rapa Therapeutics, Arcellx, Inc., Gilead Sciences, Novartis, Celgene Corporation, Genmab, Harpoon Therapeutics, Cytovia Therapeutics, Ichnos Sciences, Poseida Therapeutics, Allogene Therapeutics, Seagen Inc., Regeneron Pharmaceuticals, CFT7455, C4 Therapeutics, CARsgenTherapeutics Co.,Ltd, CELLECTAR BIOSCIENCES, INC., Nektar Therapeutics, iTeos Therapeutics, CASI Pharmaceuticals, Fate Therapeutics, Actinium Pharmaceuticals, Inc., Molecular Templates, Inc., NexImmune, Inc., LAVA Therapeutics, Sorrento Therapeutics, Chimerix, Ascentage Pharma Group Inc., Keymed Biosciences, MiNK Therapeutics, and others.
- Promising refractory multiple myeloma pipeline therapies include NEXI 002, AMG-701, ABBV 453, ALLO-605, PBCAR269A, TAK-981, ABBV-383, ORIC-533, agenT-797, ION251, UCARTCS1A, Y150, Talquetamab, Ipilimumab, LAVA-051, Felzartamab, Elranatamab, RAPA-201, CART-ddBCMA, Magrolimab, PHE885, Marizomib, Teclistamab, HPN-217, CYT-338, ISB 1342, P-BCMA-ALLO1, ALLO-715, ALLO-605, SEA-BCMA, REGN5458, NKTR-255, Iopofosine, EOS-448, CID-103, FT538, MT-0169, NEXI-002, LAVA-051, STI-6129, ONC201, APG-2575, CM336, agenT-797, and others.
- The Refractory Multiple Myeloma Companies and academics are working to assess challenges and seek opportunities that could influence Refractory Multiple Myeloma R&D. The Refractory Multiple Myeloma pipeline therapies under development are focused on novel approaches to treat/improve Refractory Multiple Myeloma.
To explore more information on the latest breakthroughs in the Refractory Multiple Myeloma treatment landscape of the report, click here @ Refractory Multiple Myeloma Pipeline Outlook
Refractory Multiple Myeloma Overview
Multiple myeloma is a cancer that starts in a type of white blood cell called a plasma cell. It’s relatively rare, making up less than 2 percent, but it’s the most common type of plasma cell tumor, according to the CDC. The survival rate of multiple myeloma has improved in recent years, but initial treatment still isn’t effective at completely getting rid of the cancer in the vast majority.
Recent Developmental Activities in the Refractory Multiple Myeloma Treatment Landscape
- In August 2022, Ipsen announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen acquires all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. Epizyme now operates as ‘an Ipsen company’ at deal close.
- In June 2022, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for talquetamab for the treatment of adult patients with relapsed or refractory multiple myeloma.
- In June 2021, AbbVie and Teneobio, Inc. announced that AbbVie exercised its exclusive right to acquire TeneoOne, an affiliate of Teneobio, Inc., and TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of relapsed or refractory multiple myeloma (R/R MM).
Request a sample and discover the recent advances in Refractory Multiple Myeloma Ongoing Clinical Trial Analysis and Medications, click here @ Refractory Multiple Myeloma Treatment Landscape
Refractory Multiple Myeloma Emerging Drugs Profile
NEXI 002: NexImmune
NEXI-002 is an endogenous (non-genetically engineered) cellular therapy and includes populations of primed antigen specific CD8+ cells directed at five specific multiple myeloma antigen targets. Generating T cells against multiple tumor targets minimizes the potential for tumor escape. In addition, NEXI-002 contains T cell subtypes that are predominantly memory phenotypes, with the majority being characterized as stem cell memory and central memory T cells. T cell products that contain high proportions of memory cells, particularly central memory and stem cell memory, have been associated with potent anti-tumor activity, long-term T cell persistence and durable anti-tumor response. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Relapsed/Refractory Multiple Myeloma.
AMG-701: Amgen
Pavurutamab (formerly AMG 701) is a half-life extended (HLE) anti-B-cell maturation antigen (BCMA) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of Relapsed/Refractory Multiple Myeloma.
ABBV 453: AbbVie
ABBV-453 is an investigational drug being developed for the treatment of R/R MM. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Relapsed/Refractory Multiple Myeloma.
Refractory Multiple Myeloma Pipeline Therapeutics Assessment
There are approx. 80+ key companies which are developing the therapies for Refractory Multiple Myeloma. The companies which have their Refractory Multiple Myeloma drug candidates in the most advanced stage, i.e. Phase I/II include, NexImmune.
For further information, refer to the detailed Refractory Multiple Myeloma Unmet Needs, Refractory Multiple Myeloma Market Drivers, and Market Barriers, click here for Refractory Multiple Myeloma Ongoing Clinical Trial Analysis
Scope of the Refractory Multiple Myeloma Pipeline Report
- Coverage: Global
- Refractory Multiple Myeloma Companies: NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, Janssen Research & Development, Bristol Myers Squibb, Lava Therapeutics, Prelude Therapeutics, Amgen, Pfizer, Rapa Therapeutics, Arcellx, Inc., Gilead Sciences, Novartis, Celgene Corporation, Genmab, Harpoon Therapeutics, Cytovia Therapeutics, Ichnos Sciences, Poseida Therapeutics, Allogene Therapeutics, Seagen Inc., Regeneron Pharmaceuticals, CFT7455, C4 Therapeutics, CARsgenTherapeutics Co.,Ltd, CELLECTAR BIOSCIENCES, INC., Nektar Therapeutics, iTeos Therapeutics, CASI Pharmaceuticals, Fate Therapeutics, Actinium Pharmaceuticals, Inc., Molecular Templates, Inc., NexImmune, Inc., LAVA Therapeutics, Sorrento Therapeutics, Chimerix, Ascentage Pharma Group Inc., Keymed Biosciences, MiNK Therapeutics, and others.
- Refractory Multiple Myeloma Pipeline Therapies: NEXI 002, AMG-701, ABBV 453, ALLO-605, PBCAR269A, TAK-981, ABBV-383, ORIC-533, agenT-797, ION251, UCARTCS1A, Y150, Talquetamab, Ipilimumab, LAVA-051, Felzartamab, Elranatamab, RAPA-201, CART-ddBCMA, Magrolimab, PHE885, Marizomib, Teclistamab, HPN-217, CYT-338, ISB 1342, P-BCMA-ALLO1, ALLO-715, ALLO-605, SEA-BCMA, REGN5458, NKTR-255, Iopofosine, EOS-448, CID-103, FT538, MT-0169, NEXI-002, LAVA-051, STI-6129, ONC201, APG-2575, CM336, agenT-797, and others.
- Refractory Multiple Myeloma Pipeline Segmentation: Product Type, Mechanism of action, Route of administration, Molecule Type
Dive deep into rich insights for drugs for Refractory Multiple Myeloma Market Drivers and Refractory Multiple Myeloma Market Barriers, click here @ Refractory Multiple Myeloma Unmet Needs and Analyst Views
Table of Contents
- Introduction
- Refractory Multiple Myeloma Executive Summary
- Refractory Multiple Myeloma Overview
- Refractory Multiple Myeloma Pipeline Therapeutics
- Refractory Multiple Myeloma Pipeline Therapeutic Assessment
- Refractory Multiple Myeloma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Mid Stage Products (Phase I/II)
- NEXI 002: NexImmune
- Early Stage Products (Phase I)
- ABBV 453: AbbVie
- Preclinical and Discovery Stage Products
- Inactive Products
- Refractory Multiple Myeloma Key Companies
- Refractory Multiple Myeloma Key Products
- Refractory Multiple Myeloma- Unmet Needs
- Refractory Multiple Myeloma- Market Drivers and Barriers
- Refractory Multiple Myeloma- Future Perspectives and Conclusion
- Refractory Multiple Myeloma Analyst Views
- Refractory Multiple Myeloma Key Companies
- Appendix
Got Queries? Find out the related information on Refractory Multiple Myeloma Mergers and acquisitions, Refractory Multiple Myeloma licensing activities @ Refractory Multiple Myeloma Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
